Bellerophon Therapeutics, Inc. (BLPH) Lowered to Hold at Zacks Investment Research
Zacks Investment Research cut shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) from a buy rating to a hold rating in a research report sent to investors on Tuesday.
According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “
Separately, ValuEngine cut Bellerophon Therapeutics from a sell rating to a strong sell rating in a report on Saturday, June 10th.
Shares of Bellerophon Therapeutics (NASDAQ BLPH) opened at 1.14 on Tuesday. The stock’s market capitalization is $40.48 million. The company has a 50-day moving average of $1.29 and a 200 day moving average of $1.34. Bellerophon Therapeutics has a 12-month low of $0.43 and a 12-month high of $1.98.
Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Analysts predict that Bellerophon Therapeutics will post ($1.12) earnings per share for the current year.
WARNING: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/26/bellerophon-therapeutics-inc-blph-lowered-to-hold-at-zacks-investment-research.html.
Several hedge funds have recently bought and sold shares of BLPH. Susquehanna International Group LLP acquired a new stake in Bellerophon Therapeutics during the second quarter valued at approximately $1,316,000. Vanguard Group Inc. boosted its stake in Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after buying an additional 211,111 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in Bellerophon Therapeutics during the first quarter valued at approximately $125,000. Finally, Renaissance Technologies LLC boosted its stake in Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after buying an additional 238,300 shares in the last quarter. 42.11% of the stock is owned by institutional investors and hedge funds.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related stocks with our FREE daily email newsletter.